Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

Rc, Young; Walton, L.; Ellenberg, S. S.; Hd, Homesley; Gd, Wilbanks; Dg, Decker; Miller, Austin; Park, R; Major, Francis J.

doi:10.1016/0020-7292(91)90270-f

Cited by 109 publications

(180 citation statements)

References 0 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…These studies have shown that patients with early-stage disease have overall survival ranging from 60 to 100% (Nguyen et al, 1993;Kosary, 1994;Averette et al, 1995;Partridge et al, 1996;Creasman et al, 2003;Jemal et al, 2006). Previous reports on ovarian cancer survival estimates were based on patients diagnosed many years ago with outdated estimates (Young et al, 1990;Yancik, 1993). In addition, many of these reports were limited by the lack of International Federation of Gynecology and Obstetrics (FIGO) staging and histologic information (Brenner, 2002;Engel et al, 2002;Barnholtz-Sloan et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…Prior reports have shown that age, stage, cell type, tumour grade, large volume ascites, and dense adhesions are important clinical and pathological prognostic factors (Dembo et al, 1990;Sevelda et al, 1990;Young et al, 1990;Finn et al, 1992;Bertelsen et al, 1993;Vergote et al, 1993;Sjovall et al, 1994;Ahmed et al, 1996;Holschneider and Berek, 2000;Trope et al, 2000). Recently, Chan et al (2008) reported on patients with high-risk early-stage patients defined as stage I, grade 3; stage IC; stage II; or clear cell epithelial ovarian cancer after adjuvant therapy from two Gynecologic Oncology Group studies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

et al. 2008

View full text Add to dashboard Cite

The objective of this study is to determine the progress and trends in the treatment and survival of women with early-stage (I -II) epithelial ovarian cancer. Data were obtained from the SEER database between 1988 and 2001. Kaplan -Meier and Cox regressions methods were employed for statistical analyses. Of the 8372 patients, the median age was 57 years (range: 12 -99 years). A total of 6152 patients (73.4%) presented with stage I and 2220 (26.5%) with stage II disease. Over the periods 1988 -1992, 1993 -1997, and 1998 -2001, 3-year disease-specific survivals increased from 86.1 to 87.2 to 88.8% (P ¼ 0.076). The number of patients that underwent lymphadenectomy has increased significantly from 26.2 to 38.7 to 54.2% over the study period (Po0.001). Of those patients who underwent staging procedures with lymphadenectomy, there was no improvement in survival over the three study periods (from 93.2 to 93.5 to 93.1%; P ¼ 0.978). On multivariate analysis, younger age, nonclear cell histology, earlier stage, lower grade, surgery, and lymphadenectomy were significant independent prognostic factors for improved survival. After adjusting for surgical staging with lymphadenectomy, the year of diagnosis was no longer an important prognostic factor. In conclusion, the use of lymphadenectomy during surgery for early-stage ovarian cancer has doubled over the last 14 years. The marginal improvement in survival demonstrated over time is potentially attributed to the increased use of staging procedures with lymphadenectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The ICON 1 study indicated that adjuvant chemotherapy improves survival and delays recurrence in patients with early-stage invasive ovarian cancer [18,19]. However, the ACTION trial concluded that optimally staged early epithelial ovarian cancers patients do not benefit from the use of adjuvant chemotherapy [20,21] The conflicting results indicates that properly staged invasive ovarian cancer stage Ia should not receive adjuvant chemotherapy, but not properly staged stage Ia patients should undergo a thorough staging procedure in order to avoid adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer

Borgfeldt

Iosif

Måsbäck

2007

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Results: During the follow-up period of median 92 months, range 11-185 months, no relapse was found in the patients with stage Ia tumors including both the borderline tumors (n=12) and the invasive well (n=9) and moderately (n=1) differentiated ovarian cancers. One patient with poorly differentiated ovarian cancer stage 1c was pregnant at 13 weeks at the primary operation.Although, unilateral oophorectomy was performed she insisted in continuing the pregnancy. At 37 weeks she had a caesarian section and the ovarian cancer was disseminated. Chemotherapy was given but she died less than a year later. No other patient received chemotherapy. In total 30 children was born by 15 patients. Prophylactic removal of the remaining ovary +/-hysterectomy was accepted only in six of the women after completing their desire to have more children. However, several of these patients do not accept the recommendation of prophylactic oophorectomy of the contra lateral ovary and hysterectomy after completion of childbearing age. Conclusions4

show abstract

“…Patients with epithelial ovarian cancers confined to the ovary or fallopian tube at initial diagnosis have a very good prognosis [39][40][41][42]. The symptoms are often very insidious and the duration of symptoms not very different between patients with early stage or advanced stage disease [13,14].…”

Section: Diagnosismentioning

confidence: 99%

Cancer of the ovary, fallopian tube, and peritoneum

Berek

Crum

Friedlander

2015

Intl J Gynecology & Obste

125

119

View full text Add to dashboard Cite

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

Cited by 109 publications

References 0 publications

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer

Cancer of the ovary, fallopian tube, and peritoneum

Contact Info

Product

Resources

About